Member Info for D-Geeman

There's already a very successful vaccine against cervical cancer. Ten million people in the UK have bee immunised since 2008, which means 57m haven't, despite it being (presumably) fairly cheap and not personalised. I can't see a bespoke cancer vaccine that's still under development having a big impact on AVCT for a long, long, time.

'The universal human papillomavirus (HPV) immunisation programme

Protecting against HPV infection to help reduce your risk of cancer

More than 280 million doses of the HPV vaccine have been given worldwide, including 120 million doses in the US and over 10 million in the UK. The HPV vaccine has been offered to all girls in school year 8 since September 2008. From September 2019 the vaccine has also been offered to year 8 boys.

This is because the evidence is clear that the HPV vaccine helps protect both boys and girls from HPV-related cancers.'

https://www.gov.uk/government/publications/hpv-vaccine-vaccination-guide-leaflet/information-on-hpv-vaccination#:~:text=Protecting%20against%20HPV%20infection%20to,year%208%20since%20September%202008.

Hanoi,

'There will be many combination treatments. The one you will never see will be AVA6000 with straight doxarubicin.'

– I've been thinking about your comment from last week.

Without being unduly negative, just suppose AVA6k was... 40% 50%... 60% as efficacious as straight dox – but NO side-effects. If people who currently take straight dox took the current standard dose plus AVA6k they'd end up with more dox in the tumour and the exact same side-effects. On the face of it that'd seem like an improvement on SoC. Alternatively , doses of straight dox might be edged down but with much more AVA6k too. Again, more dox and side effects no worse (possibly reduced) than atm.

Obviously 'it has to work' / efficacy to some extent, but safety is almost everything and they seem to have that proved already.

See the big circle with 'H' written in it? Bit of a hint?

I am sure this will have been read and posted many times before.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487063/#:~:text=FAP%20is%20known%20to%20be,%2Dassociated%20fibroblasts%20(CAFs).

But I am googling to see whether FAP is expressed only in the tumour, or also in the individual cancer cells. If the former then there might be an argument that some straight dox could be helpful to pick off circulating cancer cells which might otherwise evade AVA6K? Of course, an individual circulating cancer cell won't kill you immediately so moot point whether to kill it early, or later – and only if it goes on to cause a problem elsewhere. Killing it early would risk chemo side-effects of course.

These are some extracts:

'FAP in Cancer

While FAP expression in normal tissues is usually low or undetectable, it is overexpressed in many cancers, including 90% of carcinomas. FAP is known to be overexpressed in breast, colorectal, pancreatic, lung, bladder, ovarian and other cancers. In these cancers, FAP is usually heavily expressed in the stroma,'..

'Breast Cancer

While most studies confirmed the existence of FAP in the stroma surrounding breast cancer cells, one study identified FAP expression in the breast cancer cell lines themselves'

'Colorectal Cancer

In human colon cancer specimens, FAP expression has been identified in both cancer cells and in adjacent stromal cells, including myofiboblasts, fibroblasts and endothelial cells'

'Pancreatic Cancer

Ninety percent of pancreatic ductal adenocarcinomas (PDAC) demonstrate FAP staining. FAP expression has been identified in both the tumor stromal compartment as well as PDAC tumor cells and pancreatic cancer cell lines'

'Gastric Cancer

Gastric cancer consists primarily of two types: intestinal-type and diffuse-type. Both types express FAP, however intestinal-type does so to a larger degree. Unlike other cancers, in gastric cancer the majority of FAP expression is localized to the gastric carcinoma cells and is only weakly expressed in stromal and endothelial cells'

'In summary, FAP expression’s impact on clinical factors such as tumor type and clinical outcomes is highly variable and depends on cancer type, histological type, tumor localization and specific cellular expression (stromal vs. malignant cells).'

'Chemo will no longer be the preferred treatment it will be overtaken by gene therapy'

Or alternative scenario could be 'Chemo improves so much that it will no longer be overtaken by very expensive gene therapy'.

We are awaiting the outcome of trials so have to wait for results VR.

(Been on hols. If anyone ever want a complete break from the LSE boards I can highly recommend going for a swim with your older iphone in your pocket.)

Pjt,

‘ Watching, you take first place … mildly moronic’

I think it more likely that the post was directed at Watching than JT.

Do individual cancer cells express FAP or is it the tumour as a whole..

Morning Wyn. Thanks for your detailed thoughts. Makes sense. The only thing I might add to my original query is that when the sp was high the fact that there were serious problems couldn’t have leaked out, and I think you generally assume that the market knows a little more (or earlier) than is publicly available. It could be now that good indicators from the trial are not leaking out either?

On my phone. Hope this is adequately expressed.

Wyn, I know you take the sp as an important indicator but The Market got the valuation somewhat wrong when the sp was: 25 Apr 2021 10:31, SP 233.00.

Equally It could be wrong now at 99p couldn't it?

Bump:

MEDICAL FAIR THAILAND 2023,Today 11:08

Something different : Note Coris BioConcept reaching out to Asia attending this event .

"2023 Medical Fair in Bangkok. we will present our Range of IVD for rapid detection of AMR or Antibiotic Resistance: Carbapenemases, CTX-M"

"13 – 15 September 2023 "

https://www.medicalfair-thailand.com/?sc=hcm

https://www.corisbio.com/products/

https://www.medicalfair-thailand.com/exhibitors-2023

"We are not boosters" I seem to remember was the phrase AS used (more than once?). I wonder if he hasn't perhaps decided to over-compensate a tad, having been caught out before.

Here's a post from gmcc 25 Apr 2021 10:31, and SP was 233.00. I was searching for the terms 'avacta' + 'outstrip demand' to see what popped up. I didn't spend a long time going through a particular posters' posts:

'We have been told by Avacta that demand will outstrip supply for quality rapid LFT . Also advised that commercial sales will begin in May .

Does not really matter if sold in Europe first with UK coming along later + perhaps rest of the global market to follow .

"Multiple UK manufacturing partners and in discussion with additional overseas manufacturing capacity

In discussion with over 20 distributors covering 25 European territories for AffiDX® SARS-CoV-2 antigen rapid test for professional-use " '

It's pretty clear that AS was content to boost in 2021 and probably was genuine in his beliefs. It must have hurt him when things went badly. Perhaps his pendulum as swung too far the other way and the sp now suffers for it.

People say the LFT has no absolutely bearing now but maybe they are forgetting the psychological effect on AS.

''what are therapeutic levels anyway'?........ they told us 'eventually' but bizarrely we don't have standard Dox levels to compare against! It's going to take 1b to clarify?'

Thorn, I think AS kind of covered this in that he said they knew how much Dox it takes to kill a cancer cell in vitro (I'm not going to watch back but that's what I recall from watching it a week or two ago) as they add and add dox until they see the cells die and that they'd reached that level in the biopsies..

Of course I could have mis-remembered; 10 days is a long time for my memory these days.

If the management really do believe they'll get a commercial find with the coming drill then it makes sense not to raise now. Is it a bluff? False confidence? Only a fly on the wall in their meetings will know.

I can view the presentation (missed it too) on the h t tps://www.invest ormee tcompany.c om website. Remove the gaps. If you're registered already just sign in and use the search box for HE1. I can't post a link to the presentation directly as it's probably my own personal link.

'I didn’t have the best education... if this fails then I will probably *lose* three months'

Sparkplug, you're doing just fine. You are one of the rare people on this BB who can spell lose (rather than loose).

Sadly, and this is the trouble with ramping, also a line used by Dr Gareth Cave of (now defunct) face mask producer NNN

'Pharm 2 Farm founder's tweet preceded Remote Monitored ...

The Times

https://www.thetimes.co.uk › article

23 Nov 2020 — Gareth Cave, 46, founder of Pharm 2 Farm, became a big shareholder ... demand is about 2 million a day, so we're 'gonna need a bigger boat'.'

If they get a commercial discovery this won't matter much as HE1 will be fine but presumably the Tanzanian Govt will get a decent percentage of the value of all those bcf of HE. Does anyone recall the approximate split, if there is a split? It's probably rather complicated and buried in a contract but even a ball-park figure would be of interest.

'Can you remember DM started flying £1 around lol. He was chief ramper'.

Yes, and now we find out just how inappropriate the mineral 3" drill really was. I forget the circumstances and cash position of the company at that time but drilling with the mineral drill seems to have been an obvious long-odds gamble that predictably failed.

I guess the counter argument would be that they did find HE, just couldn't prove it.

5.6 Billion party balloons. There's the answer the last journo was looking for. No wonder the SP is up.

Someone on here explained a few months ago that the geography (flat V's sloping; dry V's wet) made the HE1 land a much more appealing prospect (Noble's slopes being less likely to trap helium etc).

Or maybe it's a false memory..